Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Christine A. Tsingos
EVP & CFO of Bio-Rad Laboratories
Ms. Christine A. Tsingos is Chief Financial Officer, Executive Vice President of Bio Rad Laboratories Inc. Previously, she was the Chief Operating Officer and Chief Financial Officer at Attest Systems, Inc., a provider of information technology asset discovery and management tools, from August 2002 to November 2002. Prior to that, Ms. Tsingos was a consultant to Attest Systems, Inc. from October 2000 to July 2002. She was the Chief Financial Officer at Tavolo, Inc., an online retailer of gourmet cookware and food, from November 1999 to September 2000, and she was Treasurer, and later Vice President and Treasurer, of Autodesk, Inc., a developer of design software, from May 1990 to November 1999.
Follow Christine A. Tsingos:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Lee Kalowski
Chief Financial Officer of Bicycle Therapeutics
Lee has served as chief financial officer at Tokai since September 2014. Prior to joining Tokai, he served as a vice president in global biotechnology equity research at Credit Suisse. In this role, Lee served as a senior research analyst covering the biotechnology industry, including numerous companies globally in the prostate cancer therapeutic area. Prior to Credit Suisse, Lee worked at Johnson & Johnson in mergers & acquisitions in the pharmaceutical group, where he was involved in the analysis and execution of several completed transactions, and in global pharmaceutical equity research at Sanford C. Bernstein and Prudential Equity Group. Lee holds a B.A., Phi Beta Kappa, in biology and economics, from Union College and an M.B.A. in finance and health care management from the Wharton School, University of Pennsylvania.
Follow Lee Kalowski:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Han Kieftenbeld
Chief Financial Officer of Amyris
Han Kieftenbeld joined Amyris as Chief Financial Officer in March 2020. He brings over 25 years of international business leadership, finance and operations experience in food, health and nutrition end-markets. Most recently, from April 2016 to April 2019, Mr. Kieftenbeld served as Senior Vice President and Chief Financial Officer of Innophos Holdings, Inc., a leading international science-based producer of essential ingredients for health and nutrition, food and beverage and industrial brands. From June 2014 to July 2015, Mr. Kieftenbeld served as the Global Chief Financial Officer at AB Mauri, a worldwide leader in bakery ingredients. Prior to that, Mr. Kieftenbeld held finance and operations roles of increasing reach and impact, including serving as Global Chief Procurement Officer of Ingredion Incorporated, and Global Chief Financial Officer of National Starch. Mr. Kieftenbeld started his career at Unilever in the Netherlands. In 2006, Mr. Kieftenbeld earned a joint master’s degree from New York University Stern School of Business, London School of Economics and Political Science, and the HEC School of Management, Paris. He holds a B.S. in Business Economics and Accounting from Windesheim University in the Netherlands.
Follow Han Kieftenbeld:
About Amyris: Amyris Biotechnologies specializes in creating renewable products focusing on fuels and chemicals.
Sam Singer
CFO of Bio-Reference Laboratories
Follow Sam Singer:
About Bio-Reference Laboratories: BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing .
Sailesh R. Saxena
CFO of ReliantHeart
Mr. Saxena is the Chief Financial Officer and Co-Founder of ReliantHeart. He played a critical role in the acquisition of the HeartAssist5 technology. He has more than twenty-five years of leadership and consulting experience in financial services, supply chain management, information technology, research and development, and operations. He has worked with numerous private equity fund companies providing financial consulting and analysis on transactions to raise capital for acquisition or investment projects. He has an MBA from SMU Cox School of Business and Electrical engineering degree from Birla Institute of Technology and Science, Pilani (BITS), India.
Follow Sailesh R. Saxena:
About ReliantHeart: ReliantHeart, Inc. is a leading innovator in mechanical circulatory support therapies for advanced stage heart failure.
Chuck Carelli
CFO of Flagship Pioneering
Chuck Carelli, CPA, joined Flagship Ventures in 2009 with 16 years of experience in financial accounting, reporting and management. After obtaining his CPA license while working in the Boston office of Deloitte & Touche, Chuck spent 13 years in various senior financial accounting and management roles at three Massachusetts-based publicly traded biotech companies. From 2004 until joining Flagship, he served in various senior financial roles with EXACT Sciences, most recently as Chief Financial Officer. Previously he was with Alkermes, Inc. serving first as Controller then as Director of Finance. He also served as Accounting Manager and then Director of Accounting at Creative BioMolecules. As CFO, Chuck is responsible for all of Flagship Ventures’ financial and tax reporting, cash flow management, fund audits, and financial administration, as well as the financial operations of Flagship’s VentureLabsTM unit. Chuck holds a BA in Accounting from Assumption College.
Follow Chuck Carelli:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Sravan K. Emany
SVP & Chief Financial Officer of Ironwood Pharmaceuticals
Sravan K. Emany is Chief Financial Officer at Ironwood. Before joining the company in 2021, Mr. Emany served as the Corporate Vice President, Commercial Excellence and Chief Strategy Officer at Integra Lifesciences Holdings Corporation, where he was responsible for the Company’s commercial support functions and led the development of their corporate strategy. Prior to Integra, Mr. Emany was at Bank of America for ten years and held roles of increasing responsibility within the Mergers & Acquisitions (M&A) business, ultimately serving as a Managing Director of the M&A group. Mr. Emany began his career working at several well-respected banking institutions including Morgan Stanley and Goldman Sachs. Mr. Emany has a B.A. in international relations and an M.A. in international relations and international economics, both from Johns Hopkins University.
Follow Sravan K. Emany:
About Ironwood Pharmaceuticals: Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Gene Castagnini
COO, CFO, CAO & Co-founder of Biocare Medical
Gene J. Castagnini, MS, MBA, co-founded Biocare Medical LLC in 1997 and serves as its Co-Owner and Chief Financial Officer. Gene Castagnini serves as the Chief Operating Officer and Executive Vice President of Biocare Medical, LLC Gene Castagnini served as the Chief Administrative Officer and Chief Financial Officer of BioGenex Laboratories. Inc., for 10 years. Gene Castagnini’s experience includes 15 years as a Director and Officer of Medi-Physics Inc., formerly a Hoffmann-La Roche Inc. subsidiary. Gene Castagnini has a BS in accounting and an MBA in Human Resource Management from the California State University school systems.
Follow Gene Castagnini:
About Biocare Medical: Biocare Medical is a provider of immunohistochemistry instrumentation.
Gerard van Hamel Platerink
Chief Financial Officer of Genalyte
Board Member at HealthMine, MedAvail Technologies & Genalyte.
Follow Gerard van Hamel Platerink:
About Accuitive Medical Ventures, Genalyte, Redmile Group: Genalyte is a life sciences company developing and commercializing innovative next-generation multiplexing technology.
Philip Siuta
Chief Operating Officer & Chief Financial Officer of Connecticut Innovations
Phil directs and supervises the finance and IT teams of CI. As CFO, he is responsible for financial reporting, budgeting, strategic planning, debt management and treasury functions. In addition to his core duties, Phil serves as project manager for the Jackson Laboratory project and the Connecticut Ecosystem. Phil joined the CI team as CFO in July of 2012 as part of the merger between CI and the Connecticut Development Authority (CDA). He was the chief financial officer for 12 years at CDA. He also spent four years as a senior accountant with Deloitte & Touche.
Follow Philip Siuta:
About Connecticut Innovations: Connecticut Innovations provides strategic capital and operational insight to to companies in high-tech industries
Leonard Bruce Jolliff
Chief Financial Officer of Vivos Inc
Leonard Bruce Jolliff, joined Advanced Medical Isotope Corporation as Chief Financial Officer in 2006. For nine years prior to joining the Company, Mr. Jolliff was a sole practitioner in the role of CFO for Hire and as a Forensic Accountant, working with companies ranging from Fortune 500 to small family operations. Mr. Jolliff is a CPA and a member of the Washington Society of CPAs. He is also a Certified Fraud Examiner and a member of the Association of Certified Fraud Examiners. Mr. Jolliff has held CFO and Controller positions in an array of industries and has worked as a CPA in public practice. Currently all of Mr. Jolliff’s energy is focused on supporting AMI’s isotope production and securing new investments which will enable the growing company to meet it’s goals.
Follow Leonard Bruce Jolliff:
About Vivos Inc: Vivos Inc develops manufacturing equipments for the production of medical isotopes used in diagnosis and treatment of diseases.
Jeanne Henry
CFO of Excel Venture Management
Jeanne joined the Excel team in 2009 and brings more than 18 years of venture capital financial management and reporting experience to the team. Previously, Jeanne was CFO and most recently COO with Atlas Venture, an international venture firm. Earlier she was an Audit Manager with Coopers & Lybrand (now PricewaterhouseCoopers). Jeanne holds a B.A. from the University of New Hampshire, an MBA from the University of Illinois, Chicago and is a Certified Public Accountant. She is a member of the AICPA, the M.A. Society of CPA’s, and a former Board member of the Private Equity CFO Association.
Follow Jeanne Henry:
About Excel Venture Management: Excel Venture Management builds companies that apply transformative life science technologies to solve problems in healthcare and beyond.
Neil Edwards
Chief Financial Officer of Vesselon
Neil Edwards is the CEO of Cellufun. Edwards served as the founding CEO of dotMobi, a mobile web services company, where he grew the company from a start-up to a multi-million dollar organization. At dotMobi he built a global customer base with multiple channel platforms and content partners that generated significant recurring revenue streams. Additionally,Mr. Edwards was instrumental in building a consortium of leading mobile brands including Nokia, Vodafone, Google, Telefonica, Telecom Italia, T-Mobile, Orascom, Microsoft, Visa and many others. Prior to dotMobi, he was instrumental in the growth of VeriSign and infoUSA,having served in senior leadership positions within both organizations.
Follow Neil Edwards:
About Forbes, Vesselon: Vesselon is a medical device company developing novel therapeutic Immuno-Oncology complexes.
Kevin Gillis
CFO / Partner of Third Rock Ventures
Kevin Gillis joined Third Rock Ventures in 2008 and oversees the operational, financial and administrative aspects of the firm. He also directs and oversees the initial operational activities for our portfolio companies. Kevin has approximately 20 years of financial experience, successfully designing, overseeing and managing the financial operations for both newly emerging and established biotech companies. Prior to joining Third Rock Ventures, Kevin was Vice President of Finance at Coley Pharmaceutical Group, supporting the company’s successful initial public offering in 2005 and overseeing the finances related to the company’s acquisition by Pfizer in 2008. Prior to Coley, Kevin served in a number of senior finance roles at Millennium Pharmaceuticals and The Coca-Cola Company. Kevin holds an MBA from Bentley University and a BA from Brandeis University.
Follow Kevin Gillis:
About Third Rock Ventures: Third Rock Ventures invests in transformational life science companies that show high growth potential
James Engelhart
Chief Financial Officer of Biohaven Pharmaceutical
Follow James Engelhart:
About Biohaven Pharmaceutical: Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
Shaun Holt
CFO of Berkeley Lights
Shaun joined Berkeley Lights in November 2015 and was appointed Chief Financial Officer in March 2016. Prior to becoming CFO, Shaun was Vice President of Finance. Prior to joining Berkeley Lights, Shaun spent 7 ½ years at Illumina, Inc. heading up various aspects of their Finance organization. His roles included Sr. Director, Global Head of R&D and Business Unit Finance, EMEA Head of Finance, Accounting and Facilities, and Commercial FP&A. He earned a B.S. in Finance from California State University, Stanislaus.
Follow Shaun Holt:
About Berkeley Lights: Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Brian Piper
Chief Financial Officer of Prelude Therapeutics
Brian Piper joined Medgenics as VP, Finance and Investor Relations in April 2014. Prior to joining Medgenics, Mr. Piper served as Senior Director, Strategic Investment Group (SIG), for Shire Pharmaceuticals, LLC from 2010 to 2013, as well as several different finance and business development roles with Shire over the past 13 years. Mr. Piper began his affiliation with Shire in 2002 as Director of Finance for Shire’s North American Development group in Rockville, MD. In 2004 he established Shire’s first US Investor Relations group, based out of Philadelphia. After three years running US Investor Relations, Mr. Piper transitioned to an alliance management role and spent two years overseas in Dublin, Ireland helping establish geographic expansion strategies. Prior to joining Shire, Mr. Piper held strategic planning roles for Celera Genomics, was Controller for a start-up Contract Research Organization, and worked as a program planner and financial analyst for Otsuka Pharmaceuticals, Inc. Mr. Piper received a B.B.A. from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.
Follow Brian Piper:
About Aevi Genomic Medicine, Prelude Therapeutics, Scorpion Therapeutics: Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival and resistance.
Ommer Chohan
Chief Financial Officer of Atlas Venture
Ommer Chohan joined Atlas in 2015 and servers as the firm’s Chief Financial Officer. He oversees the firm’s financial, legal, and operations functions. Prior to joining Atlas, Ommer was CFO/COO at Summerhill Venture Partners. Ommer joined Summerhill in 2006 and was part of the original team that spun out the firm from Bell Canada. At Summerhill Ommer was responsible for the finance, IT, and administrative functions in addition to providing financial and legal support to the investment team. Prior to Summerhill, Ommer was the VP-Finance at First Asset Management Inc. (acquired by Affiliated Managers Group), a holding company with equity interests in several leading Canadian asset management firms. Ommer received his BA-Honours, Specialist in Management from the University of Toronto, his MBA from the Johnson School at Cornell University, and earned his CPA (Ontario) while at PricewaterhouseCoopers.
Follow Ommer Chohan:
About Atlas Venture: Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Tim Cabral
Advisor (Former CFO) of Veeva
As CFO, Tim is responsible for all aspects of financial management and G&A operations. He brings over 20 years of technology finance background and nearly 10 years of software finance and operations background. Prior to joining Veeva Systems, Tim served as CFO/COO for Walsh Wireless, a wireless solutions and services company and as CFO/CoFounder of Agistics, a start-up focused on employee management services. Tim also spent more than 7 years at PeopleSoft, Inc., where he held various positions, including VP of Products & Technology Finance and Senior Director of Corporate FP&A. During his tenure as VP of Finance, Tim created and built the Operational Controller team and developed an influential business partnership model with General Managers who owned business units driving upwards of $250m in revenue. Prior to PeopleSoft, Tim served in finance positions at Chiron Corporation and LSI Logic. Tim holds a MBA in Finance and a Bachelors degree in Finance from Santa Clara University.
Follow Tim Cabral:
About Veeva: Veeva Systems is a provider of cloud-based business solutions for the global life sciences industry.
Terry Colip
Founder, Managing Member & CFO of Cell Point
Terry Colip, the Founder of Cell>Point, was a founding member of the firm and has provided his expertise from its inception. Mr. Colip has 26 years of expertise in investment banking and venture capital in the healthcare industry. Prior to founding Cell>Point, Mr. Colip worked as a healthcare consultant for Coopers & Lybrand in New York. He provided equity and investment banking services for roughly $2 billion in healthcare transactions at Underwood Neuhaus & Co., Boettcher & Co., and American Health Capital, Inc. Mr. Colip was also a founding partner in Chewton Glen Energy L.L.C. This company built two electric power plants in Illinois. Many media outlets, including Fox Business Network, Fox News, NBC News Denver, ABC News Denver, CBS News Denver, and National Public Radio, have highlighted Mr. Colip. Mr. Colip earned a B.S.I.E. in 1979 from the University of Wisconsin’s College of Engineering and an M.P.A. in finance and healthcare administration from New York University in 1981. Mr. Colip donates his time and resources to charities and organizations that focus on healthcare and disability outreach.
Follow Terry Colip:
About Cell Point: Cell Point is a biotechnology company developing universal molecular imaging agents and intra-nuclear metallic therapeutics.
William Baird
Chief Financial Officer of Bluebird Bio
William “Chip” Baird, joined bluebird in February of 2019 as chief financial officer. Chip has over 20 years of financial and strategic planning experience in the biopharmaceutical sector. Prior to bluebird, he served as CFO of Amicus Therapeutics for seven years and spent 10 years as CFO of PTC Therapeutics with responsibility for all areas of finance, investor and public relations, human resources, facilities and project management. Chip also worked in the life science practice at L.E.K. Consulting, a strategy consulting firm, and began his career at First Union National Bank in corporate debt underwriting. Chip received a B.S. from Georgetown University’s Edmund A. Walsh School of Foreign Service and an M.B.A. in finance from The Wharton School of the University of Pennsylvania.
Follow William Baird:
About 2seventy bio, Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Brian Yoor
Senior Vice President Finance & Chief Financial Officer of Abbott
Brian Yoor is Senior Vice President Finance and Chief Financial Officer. He was appointed to his current position in June 2015. He previously served as Vice President, Investor Relations. Brian joined Abbott in August 1997, and held various financial management positions of increasing responsibility, including Controller positions in the pharmaceutical, nutrition, and diagnostic businesses, before being asked to lead Abbott’s Investor Relations effort in January 2013. Prior to joining Abbott, Brian was a certified public accountant with Arthur Andersen and held financial positions in the consumer industry with the Scotts Company and Newell Rubbermaid. “In Abbott Finance, we are the stewards that enable financial reliability and growth for Abbott, “ Says Brian. “ A strong, growing company is better able to help people around the world live their healthiest lives.” Brian serves on the board of the Clara Abbott Foundation. He is a member of NIRI, the National Investor Relations Institute. He earned his bachelor’s degree in accounting at the University of Toledo in Ohio.
Follow Brian Yoor:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Georgia Erbez
Chief Financial Officer of Harpoon Therapeutics
Georgia Erbez currently works as the Chief Financial Officer for Harpoon Therapeutics. She previously worked at Artelo Biosciences, Inc. as the Member Board Of Directors.
Follow Georgia Erbez:
About Harpoon Therapeutics: Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Brett Kaplan
Chief Financial Officer of Prevail Therapeutics
Brett Kaplan is our Chief Financial Officer. Prior to Prevail, he was Managing Director at Evercore, where he spent eight years concentrating on biopharma M&A and equity financings. Prior to Evercore, Brett was an Equity Research Analyst at Cowen, where he covered large cap pharmaceuticals. Earlier in his career, he held senior positions at Cubist and Lilly focused on corporate and business development. Brett holds an MBBCh and an MBA from the University of Witwatersrand in South Africa.
Follow Brett Kaplan:
About Prevail Therapeutics: Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
Adam Cutler
Chief Financial Officer of Molecular Templates
Adam Cutler has served as Molecular Templates’ Chief Financial Officer since November 2017.Prior to joining Molecular Templates, he was Senior Vice President of Corporate Affairs at Arbutus Biopharma from 2015-2017, where his responsibilities included investor relations, business development, and corporate finance. From 2012-2015, he was a Managing Director for The Trout Group and Trout Capital, where he executed financings and advised life science companies on investor relations, capital raising, and business development. From 2000-2011, he was a biotechnology equity research analyst at Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of America Merrill Lynch. He also worked in healthcare consulting at The Frankel Group and Ernst & Young. He currently serves on the Board of Directors for Inmed Pharmaceuticals and Navidea Biopharmaceuticals. He received his B.A. in Economics from Brandeis University.
Follow Adam Cutler:
About Molecular Templates: Molecular Templates develops novel therapeutic compounds for cancer.
Thomas A. Lettero
CFO of Exact Imaging
CEO at NexGen Technology.
Follow Thomas A. Lettero:
About Exact Imaging, NexGen Technology: Exact Imaging is the developer of the ExactVu™ system, the first micro-ultrasound operating at 29 MHz that provides unmatched resolution.
David Neafus
CFO of Santi Therapeutics
David Neafus is the CFO of Santi Therapeutics.
Follow David Neafus:
About Be the Partner, Galenea, IlluminOss Medical, Intrinsic Therapeutics, PanGenX, Santi Therapeutics, Triton Resources, Wingu: Santi Therapeutics is a pharmaceutical company that focuses on the research and development of small molecule therapeutics.
Howard Horn
CFO of Vir Biotechnology
Howard Horn is the Chief Financial Officer of VIR. Previously, he led the Financial Planning and Corporate Finance functions at Biogen. Prior to joining Biogen, he held positions of increasing responsibility and was focused on the life sciences as a consultant with McKinsey & Company and as an equity research analyst at UBS. Howard holds an M.B.A from the Wharton School of the University of Pennsylvania and a B.A in Economics from Princeton University.
Follow Howard Horn:
About Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Brent Faduski
CFO of SV Health Investors
Brent Faduski joined SVLS in October 2008 as Controller and focuses on finance and accounting matters for the firm. Prior Experience: Prior to joining SVLS, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible for the accounting and finance aspects of the firm. Prior to joining CMGI @Ventures, Brent was a Senior Associate in the Technology Group at PricewaterhouseCoopers where his clients included early stage venture backed companies as well as venture capital funds.
Follow Brent Faduski:
About SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Brent Faduski
CFO of SV Health Investors
Brent Faduski joined SVLS in October 2008 as Controller and focuses on finance and accounting matters for the firm. Prior Experience: Prior to joining SVLS, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible for the accounting and finance aspects of the firm. Prior to joining CMGI @Ventures, Brent was a Senior Associate in the Technology Group at PricewaterhouseCoopers where his clients included early stage venture backed companies as well as venture capital funds.
Follow Brent Faduski:
About SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Enakshi Singh
Chief Financial Officer of Zymergen
Prior to joining Zymergen, Ena was focused on semiconductor investments at Mubadala, Abu Dhabi’s sovereign wealth fund. She spent the previous seven years in investment banking, initially at Salomon Smith Barney’s Latin America Group, later working for Merrill Lynch’s Technology Investment Banking Group. Ena studied at Cornell University and received her graduate degree at MIT Sloan School of Management.
Follow Enakshi Singh:
About Zymergen: Zymergen is a biotechnology company that specializes in machine learning, big data, and artificial intelligence.
Terry Brady
Chief Financial Officer of Farcast
With over 20 years of experience in finance and accounting, Terry joined Farcast in 2019. As the CFO, he leads HR, Finance, IT, Legal, and Business Analytics. His past experience includes success in public accounting, turnaround management consulting, and most recently as CFO of a large manufacturing company. He holds undergraduate and graduate degrees from the University of Notre Dame as well as an MBA from the Kellogg School of Management at Northwestern University.
Follow Terry Brady:
About Farcast: Farcast develops a diagnostic platform that delivers powerful predictions for personalized cancer treatment selection and drug development.
Gary Martell
CFO of Skyhawk Therapeutics
Follow Gary Martell:
About Blu Homes, Skyhawk Therapeutics: Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.
Kathryn E. Falberg
Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals
Kathryn Falberg was appointed our Executive Vice President and Chief Financial Officer in March 2012. She served as our Senior Vice President and Chief Financial Officer from 2009 to 2012. Her responsibilities include finance, strategy, corporate development and IT. From 1995 through 2001, Kathryn Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. From 2001 through 2008, Kathryn Falberg was President of Canyon Capital & Consulting, a private investment and consulting firm, where she worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies. From February to November 2009, she was Chief Financial Officer and Chief Operating Officer at ARCA biopharma, Inc., a biopharmaceutical company. Kathryn Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant (inactive). Kathryn Falberg currently serves on the boards, and is chair of the audit committees, of biopharmaceutical companies Halozyme Therapeutics, Inc. and Medivation, Inc.
Follow Kathryn E. Falberg:
About Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.
Ken Myszkowski
Chief Financial Officer of Arrowhead Pharmaceuticals
Follow Ken Myszkowski:
About Arrowhead Pharmaceuticals: Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Karen Adams
CFO of Arrivo BioVentures LLC
Karen Adams has a 30 year career as a finance professional working with companies across a broad range of industries with the last 15 years focused on life sciences and technology. After starting her career as an Internal Auditor with International Paper Company, Inc., Karen Adams has held financial leadership positions with companies in software, professional services and biotechnology industries. Most recently, Karen Adams has been part of the management team, in the CFO role, responsible for the creation and sale of two companies (Addrenex Pharmaceuticals to Shionogi Pharma and Neuronex to Acorda Therapeutics) and Aerial BioPharma’s ADX-N05 asset sale to Jazz Pharmaceuticals. While Karen Adams life sciences experience has been primarily focused on early-stage, privately funded companies she was brought on as Assistant Controller at Millennium Pharmaceuticals, Inc. during its merger with COR Therapeutics – among the largest such mergers in the history of the biotech industry at that time. After Millennium Pharmaceuticals, Karen Adams went on to work with several early stage biotechnology ventures including Surface Logix, Inc., Compound Therapeutics, Inc., Galenea Corporation, BG Medicine, Inc., and Micell Technologies, Inc. Karen Adams contribution was concentrated on the creation of dynamic, integrated financial forecasting models as well as the implementation of core business structure. Karen Adams graduated from Boston College earning a BS in Management, majoring in Finance.
Follow Karen Adams:
About Arrivo BioVentures LLC, Emergo Therapeutics, KJA Associates, QuatroBio: Arrivo BioVentures is a pharmaceutical development company which focuses on identifying biologics and molecules to improve patient care.
Karen Adams
CFO of Arrivo BioVentures LLC
Karen Adams has a 30 year career as a finance professional working with companies across a broad range of industries with the last 15 years focused on life sciences and technology. After starting her career as an Internal Auditor with International Paper Company, Inc., Karen Adams has held financial leadership positions with companies in software, professional services and biotechnology industries. Most recently, Karen Adams has been part of the management team, in the CFO role, responsible for the creation and sale of two companies (Addrenex Pharmaceuticals to Shionogi Pharma and Neuronex to Acorda Therapeutics) and Aerial BioPharma’s ADX-N05 asset sale to Jazz Pharmaceuticals. While Karen Adams life sciences experience has been primarily focused on early-stage, privately funded companies she was brought on as Assistant Controller at Millennium Pharmaceuticals, Inc. during its merger with COR Therapeutics – among the largest such mergers in the history of the biotech industry at that time. After Millennium Pharmaceuticals, Karen Adams went on to work with several early stage biotechnology ventures including Surface Logix, Inc., Compound Therapeutics, Inc., Galenea Corporation, BG Medicine, Inc., and Micell Technologies, Inc. Karen Adams contribution was concentrated on the creation of dynamic, integrated financial forecasting models as well as the implementation of core business structure. Karen Adams graduated from Boston College earning a BS in Management, majoring in Finance.
Follow Karen Adams:
About Arrivo BioVentures LLC, Emergo Therapeutics, KJA Associates, QuatroBio: Arrivo BioVentures is a pharmaceutical development company which focuses on identifying biologics and molecules to improve patient care.
Daniel Schneiderman
Chief Financial Officer of First Wave BioPharma
Follow Daniel Schneiderman:
About First Wave BioPharma: First Wave BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies.
Glenn S. Boehnlein
Chief Financial Officer & Vice President of Stryker
Follow Glenn S. Boehnlein:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Jaime Bartushak
CFO of Citius Pharmaceuticals
Follow Jaime Bartushak:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Kim Witmer
Senior Vice President & Chief Financial Officer & Treasurer of Salk Institute for Biological Studies
Kim Witmer is Senior Vice President, Chief Financial Officer and Treasurer of the Salk Institute. She oversees all financial activities of the Salk, including financial reporting and treasury functions, research accounting, annual budgets, procurement, grants administration and endowment/investment management. Prior to joining the Salk, Witmer worked for the international accounting firm of Deloitte & Touche. Witmer also acts as past President of AIRI, the Association of Independent Research Institutes, as well as serving on AIRI’s Board of Directors and Government Affairs Committee. AIRI brings together nearly 100 independent, not-for-profit biomedical and behavioral research institutes whose mission is to enhance the ability of its members to improve human health and advance knowledge. Additionally, Witmer served as the Chief Financial Officer and Treasurer of the Sanford Consortium for Regenerative Medicine (SCRM), and currently holds a position on SCRM’s Administrative Council as the Salk representative. She is a Certified Public Accountant and holds a B.S. in business administration from San Diego State University.
Follow Kim Witmer:
About Salk Institute for Biological Studies: Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology.
Susan M. Kanaya
Senior Vice President, Finance, Chief Financial Officer and Secretary of ChemoCentryx
Ms. Susan M. Kanaya has served as our Senior Vice President, Finance, and Chief Financial Officer since January 2006, and Secretary since February 2006. Prior to joining us, Ms. Kanaya served as Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., a biotechnology company, from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., a biotechnology company, from 1994 to 1999, most recently as Vice President, Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.
Follow Susan M. Kanaya:
About ChemoCentryx: ChemoCentryx develops orally administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
Phillip Donenberg
Senior Vice President, Chief Financial Officer of AveXis
Phillip brings more than 23 years of leadership expertise in finance, mergers and acquisitions (M&A) and operations focused in the pharmaceutical and healthcare industries. His background includes recent experience with a gene therapy company, AveXis, Inc., where he served as the Chief Financial Officer and Senior Vice President until June 15, 2018, following its acquisition by Novartis. Phillip has held leadership roles overseeing strategic transactions, financing management and accounting operations, controls and reporting processes for growing life sciences companies. Most recently, he was Chief Financial Officer and Senior Vice President of Depomed, Inc. Previously, Phillip was the Chief Financial Officer at RestorGenex Corporation from 2014 to 2016, when RestorGenex merged with Diffusion Pharmaceuticals, Inc. From 1998 to 2013, he served as the Chief Financial Officer at BioSante Pharmaceuticals, Inc. until the merger of the company with ANIP Pharmaceuticals, Inc. Phillip earned a bachelor’s degree in accountancy from the University of Illinois, and he is a Certified Public Accountant.
Follow Phillip Donenberg:
About AveXis, Jaguar Gene Therapy: AveXis is a Biotech company is focused on developing gene therapy for patients with rare and life-threatening neurological genetic diseases.
Linda C. Bain
CFO of Codiak Biosciences
Linda C. Bain, CPA, has served as our vice president of finance and business operations since October 2011 and as our treasurer since March 2013. Previously, she served as vice president of corporate finance at Genzyme from September 2008 to September 2011, at Fidelity Investments from September 2007 to September 2008 and a number of positions at AstraZeneca from May 2000 to September 2007. She received her B.S. from the University of the Orange Free State in South Africa.
Follow Linda C. Bain:
About Codiak Biosciences: Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Henry Edmunds
acting CFO of Sepragen
Dr. Edmunds is currently acting as Chief Financial Officer of Sepragen. He also serves as President of Biopheresis. Previously, he served as Vice President and Chief Financial Officer of Prometheus, a pharmaceutical company. He also served as Vice President of Corporate Development and Chief Financial Officer of SangStat Medical Corporation, and as Director of Business development at Genencor, Inc. Dr. Edmunds received his Ph.D. in Biotechnology from the University of California, Berkeley and his M.B.A. from the Stanford School of Business.
Follow Henry Edmunds:
About Sepragen: Sepragen provides break-through products and processes to the biotechnology and nutraceutical industries.
David Socks
Co-founder, CFO, and CBO of HilleVax
Follow David Socks:
About HilleVax, Phathom Pharmaceuticals: HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
Paul Herendeen
Executive Vice President and Chief Financial Officer of Zoetis India Ltd
Paul Herendeen is executive vice president and chief financial officer (EVP and CFO) of Zoetis. In his role, Herendeen oversees the company’s Finance and Information Technology organizations and serves as part of the Zoetis Executive Team, reporting to CEO Juan Ramón Alaix. Herendeen brings more than 30 years of broad financial experience and leadership to his role at Zoetis, including 16 years as CFO of Warner Chilcott and MedPointe. From 2005 to 2013, Herendeen served as CFO at Warner Chilcott, a specialty pharmaceuticals company, which had a successful IPO in 2006, grew its revenue and profitability, and was acquired by Actavis in 2013. He joined Warner Chilcott after four years as EVP and CFO of MedPointe, a privately held health care company. He had been Warner Chilcott’s CFO from 1998 until 2000, joining the company after representing one of its lead investors on Warner Chilcott’s Board of Directors. Herendeen helped grow the company’s revenues and conduct its first successful IPO, and later helped complete the company’s acquisition by Galen PLC. From 1989 to 1998, Herendeen spent nine years as a principal investor at both Dominion Income Management and Cornerstone Partners, where he worked on investments as well as mergers and acquisitions for the firms and their portfolio companies. He also spent the early part of his career in banking and public accounting, having held various positions with the investment banking group of Oppenheimer & Company, the capital markets group of Continental Bank Corporation, and as a senior auditor with Arthur Andersen & Company. Herendeen earned a Master of Business Administration (MBA) from the University of Virginia’s Darden School of Business, and holds a bachelor’s degree in Business Administration from Boston College.
Follow Paul Herendeen:
About Bausch Health, Zoetis India Ltd: Zoetis provides healthcare services for animal.
Shalini Sharp
CFO of Ultragenyx Pharmaceutical
Shalini Sharp joined Ultragenyx in May 2012 as Chief Financial Officer and Senior Vice President, Finance. She is a member of the Senior Management Team and is responsible for leading the corporate finance function, including strategic financial planning, accounting, budgeting and forecasting, financial analysis, general risk analysis, and financing activities. Shalini Sharp is a member of the Board of Directors of Agenus Inc. (formerly Antigenics Inc.), a publicly traded biotechnology firm, where she served as Chief Financial Officer from 2006 to 2012. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development. Prior to Agenus, Shalini Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as chief of staff to the Chairman of the Board of Directors during that company’s restructing. With 16 years of industry experience, Shalini Sharp has spearheaded numerous financing and business development transactions that have been critical to the success of Agenus and Elan. Prior to Elan, Shalini Sharp was a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices.
Follow Shalini Sharp:
About Ultragenyx Pharmaceutical: Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
David Wood
CFO of ESSA Pharma
David Wood has been CFO of ESSA since October 2013. He is responsible for managing all financial aspects of ESSA’s business and matters related to compliance and corporate governance. David has over 30 years of experience in management of both large and early stage companies in North America and the U.K. From 2003 to 2013, he was Head of Finance, Secretary and Treasurer at Celator Pharmaceuticals Inc. Prior to 2003, he was Managing Director of Cubist Pharmaceuticals (UK) Ltd., and Finance Director at TerraGen Discovery, Inc. During 18 years in the biopharmaceutical industry, David has overseen several M&A transactions and numerous financings, raising over $100 million. David began his career in the finance and exploration departments of Chevron Corp. He received a B.Sc. in Biology from Queen’s University, an M.B.A. from University of Western Ontario and holds a CPA, CMA accounting designation. He served on the governing body of the National Research Council of Canada from 2008 to 2014.
Follow David Wood:
About ESSA Pharma: ESSA Pharma is a biotechnology company that develops new drugs for prostate cancer.
Ethan Einwohner
Chief Financial Officer of Specified Testing Labs
I Ethan Einwohner formed Specified Testing Labs, LLC, a roll-up of environmental testing laboratories, in August 2013. Under Specified, Ethan led the acquisitions of the testing lab assets of: International Hydronics Corporation (Oct 2013); New Jersey Analytical Labs (Nov, 2013), CNA Environmental (Dec 2013); and Smith Environmental Labs (Apr 2014). At Specified, Ethan manages all financial aspects of the firm and has responsibilities for its acquisition and integration activities. With his laboratory operations team, Ethan forms and executes company strategy .
Follow Ethan Einwohner:
About CNA Environmental, Recurrent Capital Bridge Fund, Specified Testing Labs: Specified Testing Laboratories, LLC is a holding company of testing laboratories and related operating companies. Formed in September .
Diane Marcou
Consulting CFO of Satellite Bio
Ms. Marcou has provided financial and strategic advisory services to a number of venture-backed technology companies, including ByAllAccounts, Inc., Fluidnet Corporation, Radianse and T2 Biosystems. Prior to working as an independent financial consultant, she was Chief Financial Officer and Vice President of Finance and Administration for Incentive Systems (dba Centive), a privately held venture-funded software company, and Chief Financial Officer at Workgroup Technologies, a publicly traded software company with domestic and international operations. Ms. Marcou earned a B.S. in Business Administration from Boston College, and her CPA from PricewaterhouseCoopers, formerly Coopers & Lybrand.
Follow Diane Marcou:
About Boston MicroFluidics, Cytrellis Biosystems, Incentive Systems, Satellite Bio, Workgroup Technology: Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering.
Bryan Giraudo
Chief Financial Officer & COO of Gossamer Bio
Mr. Giraudo is the Chief Financial Officer of Gossamer Bio. Previously, he was Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Bryan was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group. Bryan received his B.A. from Georgetown University.
Follow Bryan Giraudo:
About Gossamer Bio: Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
Joseph Talamo
Senior Vice President and Chief Financial Officer of HiberCell
Joseph Talamo is the Senior Vice President and Chief Financial Officer at HiberCell.
Follow Joseph Talamo:
About HiberCell: HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis.
Jim Berend
Chief Financial Officer & Executive Vice President of USMD
Jim Berend serves as chief financial officer and executive vice president of USMD Holdings. In his position, Jim oversees all of USMD’s finance functions and activities. Jim has more than 35 years of experience in healthcare finance, having served as a CFO, consultant, auditor and partner at international accounting and consulting firms. He has extensive experience in all aspects of healthcare accounting and finance across the care continuum. Previously, Jim served as CFO and executive vice president of a company operating surgical hospitals in Texas. He was responsible for finance and accounting, centralized billing office, materials management and hospital financial operations.Jim received his Bachelor of Business Administration, with highest honors, from The University of Texas in Austin. He is a licensed CPA in Texas.
Follow Jim Berend:
About USMD: USMD Holdings develops, operates and manages entities that deliver diagnostic, therapeutic and hospital-based health care to patients.
Aaron Freidin
Chief Financial Officer of Grail
Aaron Freidin is Chief Financial Officer at Grail.
Follow Aaron Freidin:
About Grail: Grail develops a pan-cancer screening test designed to detect cancers at an early stage.
Martyn Ansell
Chief Financial Officer and Vice President, Finance of Molecular Devices
Martyn joined Molecular Devices in June 2012 as Vice President, Finance. Prior to joining Molecular Devices he was Chief Financial Officer of Vistec Semiconductor Systems, a global leader in the development and manufacture of electron-beam lithography equipment for the semiconductor industry. Prior to joining Vistec, Martyn spent over 12 years at Applied Materials, a manufacturer of semiconductor equipment, where he held a number of senior financial management positions in business development and within several product divisions. In addition, he has held positions at Coopers & Lybrand, in San Jose, California and Ernst & Young in the U.K. Martyn received a BA in Accounting and Finance with Honors from the Manchester Metropolitan University, Manchester, England and is a member of the American Institute of Certified Public Accountants.
Follow Martyn Ansell:
About Molecular Devices: Bioanalytical Systems and Solutions
Michael Banks
CFO of Kineta
Michael Banks serves as the Chief Financial Officer of Kineta.
Follow Michael Banks:
About Kineta: Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.
Peter Aranow
Chief Financial Officer of Respiratory Motion
Mr. Aranow is the Chairman of Boynton Angels, a Worcester investor group that invests in start-up companies. Peter Aranow has spent 30 years in finance. For 17 years he was in the investment banking department of Bear Stearns & Co., where he worked on debt and equity financings, mergers and acquisitions, and was the investment banker responsible for Bear Stearns’ initial public offering. For the following 13 years he served as chief financial officer for a number of public and privately-owned companies, including an Internet advertising company and the New York City Off-Track Betting Corporation. Mr. Aranow holds an BA from Harvard College and an MBA from Harvard Business School.
Follow Peter Aranow:
About Harvard Business School Community Action Partners, Off Track Betting New York, Respiratory Motion: Respiratory Motion ExSpiron is FDA and CE Mark cleared and non-invasively measures minute ventilation, the fundamental unit of breathing.
David Lewis
Co-Founder & CFO of LunaDNA
David Lewis is a Co-Founder and Chief Financial Officer at LunaDNA and LunaPBC.
Follow David Lewis:
About Ganley Investment Group, LunaDNA, LunaPBC: The first and largest health and DNA research platform owned by its community.
Alexander Casdin
Chief Operating Officer & Chief Financial Officer of Epirium
Alexander Casdin is the Chief Financial Officer (CFO) of Epirium Bio. He has broad financial and operational expertise, with more than 20 years of experience as a healthcare executive and investor. Prior to joining Epirium, Mr. Casdin was founder, Chief Executive Officer (CEO) and portfolio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as CFO of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals. Mr. Casdin was a founder and senior advisor at Casdin Advisors, LLC; CEO and portfolio manager at Cooper Hill Partners, LLC, a healthcare investment fund; and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the Dreyfus Corporation as a senior managing analyst covering pharmaceuticals, biotechnology and medical devices. Mr. Casdin has been on the board of directors for multiple life science companies including Erasca, Inc., Dusa Pharmaceuticals, Inc., and Ignyta, Inc. Mr. Casdin received an M.B.A from Columbia Business School and a B.A. in political science from Brown University.
Follow Alexander Casdin:
About Epirium, Epirium: Epirium Bio is a clinical stage bio pharmaceutical company.
Jeffrey B. McGroarty
Chief Financial Officer of Annovis Bio
Follow Jeffrey B. McGroarty:
About Annovis Bio: Annovis Bio develops novel treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.
Reid McCarthy
Consulting Chief Financial Officer of Annovis Bio
Follow Reid McCarthy:
About Annovis Bio: Annovis Bio develops novel treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.
Douglas Larson
Group Chief Financial Officer of Beyond Air
Douglas Larson is the Group Chief Financial Officer at Beyond Air.
Follow Douglas Larson:
About Beyond Air: Beyond Air is a biotechnology company focused on the development of drugs for the treatment of lung infections.
Kimi Iguchi
CFO of SAGE Therapeutics
Kimi Iguchi joined SAGE Therapeutics in March 2013 as Chief Financial Officer with more than 15 years of progressive experience managing finance, accounting, operations and human resources in emerging life science companies. Prior to joining SAGE, Ms. Iguchi has led the organizational development of strategic business plans, portfolio management, deal structure, fund raising, financial planning, and operations infrastructure design and growth. She has held positions at Warp Drive Bio, LLC, Santhera Pharmaceuticals, Cyberkinetics, Millennium Pharmaceuticals and Biogen, Inc. She began her career at PricewaterhouseCoopers LLP, Boston. Ms. Iguchi holds a B.A. in chemistry from Drew University, received her MBA from Northeastern University, and earned her CPA in Massachusetts.
Follow Kimi Iguchi:
About SAGE Therapeutics: SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Mary Reumuth
Chief Financial Officer of Kala Pharmaceuticals
Ms. Reumuth joined Kala in February of 2014 as Senior Director, Finance and Corporate Controller. She brings with her nearly 20 years of diversified finance and accounting experience. Ms. Reumuth was formerly Corporate Controller for Enobia Pharma (acquired by Alexion Pharmaceuticals). Prior to her tenure at Enobia, she spent several years at Genzyme Corporation in Cambridge, MA through the acquisition of ILEX Oncology in San Antonio, Texas. Ms. Reumuth began her career as an auditor with the San Antonio office of Ernst & Young LLP. Ms. Reumuth earned her business degree from Texas A&M University – Corpus Christi and is a Certified Public Accountant.
Follow Mary Reumuth:
About Kala Pharmaceuticals: Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues.
Algimantas Chesonis
CFO of Sweetwater Energy
Algimantas Chesonis currently works as Chief Financial Officer at Sweetwater Energy.
Follow Algimantas Chesonis:
About Sweetwater Energy: Sweetwater Energy is a company that produces concentrated sugar from multiple non-food plant materials.
Algimantas Chesonis
CFO of Sweetwater Energy
Algimantas Chesonis currently works as Chief Financial Officer at Sweetwater Energy.
Follow Algimantas Chesonis:
About Sweetwater Energy: Sweetwater Energy is a company that produces concentrated sugar from multiple non-food plant materials.
Judy Koh
Managing Director/Chief Financial Officer of Bay City Capital
Judy Koh, MBA, CPA, is an Operating Partner and the Chief Financial Officer at Bay City Capital and has been with the firm since April 1998.
Follow Judy Koh:
About Bay City Capital, Illumina Ventures: Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Edward Freedman
Chief Financial Officer of Faze Medicines
Ed is head of operations focusing on firmwide operations and providing financial, legal and operational guidance and support to Atlas’ seed stage companies. Ed has more than 20 years of leadership experience directing finance, legal and operations activities in companies across multiple industries. Prior to joining Atlas in 2018, Ed served as CFO at both KSQ Therapeutics and XTuit Pharmaceuticals. Prior to KSQ and XTuit, Ed was CFO and general counsel at Oasys Water, a global technology company in the energy and natural resource industries. Ed previously served as general counsel of Flagship Ventures (now Flagship Pioneering) and started his legal career at Testa, Hurwitz & Thibeault, LLP. Before going to law school, Ed was an accountant at Arthur Andersen & Co. Ed earned his JD from Boston College Law School and his BSBA in Accounting from Boston University.
Follow Edward Freedman:
About Faze Medicines, Freedman Advisors, Pandion Therapeutics: Faze Medicines is a biotechnology company.
Arthur Polk
Chief Financial Officer & Co-Founder of PetDx
Arthur Polk is the Chief Financial Officer and a Co-Founder at PetDx.
Follow Arthur Polk:
About PetDx: PetDx is a molecular diagnostics company dedicated to the detection and treatment of cancer in pets.
Lauren Silvernail
CFO and EVP Corporate Development of Evolus
Lauren Silvernail is the Chief Financial Officer and Executive Vice President, Corporate Development at Evolus.
Follow Lauren Silvernail:
About Evolus: Evolus medical aesthetics focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments.
Jeff Poulton
Chief Financial Officer of Alnylam Pharmaceuticals
Follow Jeff Poulton:
About Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Peter Collum
Chief Financial Officer and Chief Business Officer of Pharnext
More than 17 years’ experience in healthcare investment banking focused on M&A, financing and business development transactions. Previously partner at MTS Health Partners for public and private life sciences companies both in the US and abroad, and worked in the healthcare investment banking group at Bank of America. Started at Roche as an engineer.
Follow Peter Collum:
About Pharnext: Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.
Jim Prather
Chief Development Officer & CFO of WAVi
President WAVi Medical at WAVi.
Follow Jim Prather:
About WAVi, WAVi: WAVi is a medical technology company based in Englewood, Colorado.
Paul Kim
Chief Financial Officer of Fulgent Therapeutics
Paul Kim has served as Fulgent Chief Financial Officer since 2016. Prior to his service for us, Mr. Kim served as Chief Financial Officer of Cogent, a publicly traded biometric identification services and product company from 2004 until 2011. Mr. Kim’s past experience also includes service as the Chief Financial Officer of JNI Corporation, or JNI, a publicly traded storage area network technology company, from 2002 until 2003, as Vice President, Finance and Corporate Controller at JNI from 1999 to 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from 1998 until 1999. From 1996 to 1998, Mr. Kim was the Corporate Controller for Interlink Computer Sciences, Inc., a publicly traded enterprise software company. From 1990 to 1996, Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager. Mr. Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.
Follow Paul Kim:
About Fulgent Therapeutics: Fulgent Therapeutics, LLC is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics.
Paul Manners
Chief Financial Officer of Trak
Follow Paul Manners:
About Trak: Sandstone Diagnostics provides an integrated wellness technology that empowers consumers to measure, monitor, and improve their health.
Brian M. Campbell
CFO of HemoShear Therapeutics
Campbell has been an entrepreneur and an economic consultant throughout his 40-year business career. He began in 1968 with an aviation consulting firm in New York and was promoted to Vice President of their Washington office in 1973. In 1977, Campbell co-founded Midway Airlines, Inc., the first new start-up carrier after airline deregulation, where he served as CFO and participated in the raising of venture capital to fund the airline’s launch. Campbell returned to the aviation consulting business in 1983 and is currently chairman of The Campbell-Hill Aviation Group in Alexandria, VA. Campbell has assisted numerous start-up companies with business plan preparation, financial forecasting, detailed market analyses, and strategic planning studies. Campbell currently serves as vice chairman and acting CFO of Dynamic Literacy, LLC, advisor to Targeson, LLC, a University of Virginia (UVa)-based biotechnology company, advisor and investor in BioMotion Analytics, LLC, is a member of the advisory board of UVa’s Heart and Vascular Center, and serves on the UVa Patent Foundation Advisory Panel. Campbell earned a Bachelor of Commerce from McGill University, an MBA from the University of Western Ontario, and a PhD in Business Administration from Columbia University.
Follow Brian M. Campbell:
About Dynamic Literacy, HemoShear Therapeutics: HemoShear Therapeutics develops new treatments for patients with rare metabolic disorders.
Jeff Elliot
Chief Financial Officer of Exact Sciences
Follow Jeff Elliot:
About Exact Sciences: Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Adam Derbyshire
Chief Financial Officer of Salix Pharmaceuticals
Adam Derbyshire is the CFO at Salix Pharmaceuticals.
Follow Adam Derbyshire:
About Salix Pharmaceuticals: Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Adam Logal
Sr. Vice President & Chief Financial Officer of OPKO Health
Mr. Logal has served as OPKO’s Sr. Vice President and Chief Financial Officer since April 2014 and as OPKO’s Vice President of Finance, Chief Accounting Officer and Treasurer since March 2007. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. Mr. Logal currently serves on the board of directors of SciVac Therapeutics, Inc. (TSX: VAC), a commercial-stage biopharmaceutical company.
Follow Adam Logal:
About OPKO Health: Opko Health engages in the discovery and development of novel and proprietary technologies for pharmaceuticals and diagnostics.
Michael A. Doyle
Chief Financial Officer of Quanterix
With nearly 30 years of financial and management experience at major companies, Michael serves as Forrester’s chief financial officer (CFO). He leads Forrester’s finance team and oversees the company’s relationships with investors, market analysts, accountants, and bankers. Michael’s responsibilities also include both managing day-to-day financial activity as well as planning for Forrester’s long-term opportunities. Prior to joining Forrester, Michael was CFO of EasyLink Services, a publicly traded global telecommunications messaging provider. There he led an organization focused on improving productivity and financial planning and reporting. Previously, Michael served as CFO at Dun & Bradstreet, North America, responsible for driving the cash flow process improvement to record cash performance, and successfully integrating the Hoovers acquisition. Michael began his career at Continental Can where his tenure included financial management roles at the leading diversified packaging manufacturer. For the next 14 years, he held senior financial management positions at Cendant, Allied Signal, PepsiCo, as well as marketing and strategy positions at Cendant and PepsiCo. Michael holds a Master of Business Administration from New York University and a Bachelor of Business Administration in finance from the University of Notre Dame.
Follow Michael A. Doyle:
About Quanterix: Quanterix is a platform for single molecule analysis that supports clinical diagnostics, drug development, and life science researches.
Ted Jeong
Chief Financial Officer of Clene Nanomedicine
Ted Jeong is the Chief Financial Officer of Clene Nanomedicine. He has a master’s degree in Finance at The Johns Hopkins University.
Follow Ted Jeong:
About Clene Nanomedicine: Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Jason McCarthy
Chief Financial Officer of Arbor Pharmaceuticals
Jason brings to Arbor over 15 years of progressive accounting, auditing and finance experience from a mixture of public and private companies. Jason most recently managed the accounting function and was responsible for all SEC filings at Lodgian, Inc., an owner and operator of franchised hotels. Prior to Lodgian, Inc., Jason successfully founded his own company specializing in Sarbanes-Oxley implementations and internal control consulting for some of the top public companies in Atlanta. In addition, Jason also worked for PricewaterhouseCoopers in their audit function specializing in real estate and manufacturing. Jason is a Certified Public Accountant in the state of Georgia and a graduate of Ohio University with dual bachelor’s degrees in Accounting and Management Information Systems.
Follow Jason McCarthy:
About Arbor Pharmaceuticals, Sarbanes-Oxley: Arbor Pharmaceuticals is a specialty pharmaceutical company developing late-stage therapeutic products for common pediatric conditions.
David Cordo
CFO of Metamark Genetics
Mr. Cordo began his career in the life sciences industry in 1990. He held senior management positions in finance at Biogen Idec during his seven-year tenure where he put in place the financial infrastructure for the worldwide commercial launch of Avonex. For seven years, he was the Treasurer of Millennium Pharmaceuticals. At Millennium, he led finance teams in the raising of an $800 million follow-on equity offering and a $400 million convertible debt offering. He also led finance teams for three acquisitions. Dave has been interim chief financial officer for several venture capital backed life science companies, including Dicerna Pharmaceuticals, Epizyme, Inc., Link Medicine Corporation, TransForm Pharmaceuticals, Avila Therapeutics and Alinea Pharmaceuticals, and consulting on strategic financial issues for public and private life science companies. He is a Certified Public Accountant and holds an M.B.A. degree from Nichols College and a B.S.B.A. degree from Stonehill College. He is an active member of the Executive Committee of the Wake Forest University Parents’ Council and consults for several charitable organizations.
Follow David Cordo:
About Metamark Genetics, Novartis, Potenza Therapeutics, Semma Therapeutics: Metamark Genetics develops prognostic and predictive diagnostic tests that enable personalized treatment planning for cancer patients.
Dave Lowrance
Chief Financial Officer of Savara Pharmaceuticals
David Lowrance has served as Savara’s Chief Financial Officer since November 2016. From September 2014 to October 2016, Mr. Lowrance served as the Chief Financial Officer and Treasurer of Edgemont Pharmaceuticals, a fully-integrated specialty pharmaceutical company with multiple marketed products in the CNS space. From April 2011 to September 2014, Mr. Lowrance served as the Chief Financial Officer and Secretary of Acucela Inc., a clinical-stage biotechnology company that specializes in ophthalmic therapeutics, where he was responsible for overseeing all aspects of Acucela’s day-to-day operations, business development and growth endeavors, investor relations and corporate communications. While at Acucela, Mr. Lowrance helped lead a $162 million international IPO, with a listing on the Tokyo Stock Exchange. From March 2003 to April 2011, Mr. Lowrance was Vice President and Chief Financial Officer of Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on commercializing branded prescription products, where he oversaw all aspects of finance and accounting, business and growth strategy and product development. Mr. Lowrance, a CPA, holds a B.B.A. in Accounting from the University of Georgia.
Follow Dave Lowrance:
About Savara Pharmaceuticals: Savara Pharmaceuticals develops an inhaled antibiotic for MRSA infection in cystic fibrosis.
Jason Brandt
Chief Financial Officer & Chief Compliance Officer of Sante Ventures
Jason was hired by Santé in 2017 to manage the financial and compliance activities and to ensure the firm meets all regulatory requirements. Previously, Jason served as the Regional Head of Fund Services for the Americas for Maples Fund Services where he focused on growing the NA business through expansion of administration, middle-office and risk services to investment managers, institutional investors and family offices. Prior to that, Jason served as Director of Client Services for Alternative Fund Services with Deutsche Bank in London, managing all client service relationships with hedge funds, fund of funds, private equity and real estate funds across EMEA and Asia. Prior to Deutsche Bank, Jason served as Managing Director / COO of Hedgeworks, and positions at Capital Guardian Trust Company, Ernst & Young and Coopers & Lybrand. Jason holds a Bachelor of Science in Accounting from Loyola Marymount University, is a current member of the CFA Institute, and Certified Public Accountant.
Follow Jason Brandt:
About Sante Ventures: Santé Ventures is a life sciences venture capital firm that invests in early-stage companies developing innovative medical technologies.
Dane Saglio
CFO of Helomics
Dane Saglio serves as Chief Financial Officer of Helomics®. Formerly, Mr. Saglio was the CFO of RegeneRx Biopharmaceuticals, Inc; SuperNova Diagnostics; New Generation Biofuels; EntreMed Biopharmaceuticals; and held senior financial positions with Sterling Software, Inc. and Public Communication Associates. Mr. Saglio also has extensive public and private company experience along with a wide range of corporate finance and strategic transactions experience. Dane earned his B.S. in business administration from the University of Maryland and is a licensed CPA (inactive).
Follow Dane Saglio:
About Helomics, RegeneRx: Helomics provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services.
Fred Driscoll
Chief Financial Officer of Flexion Therapeutics
Fred Driscoll has more than 20 years of experience in financial management of life sciences companies, most recently as the Chief Financial Officer at Flexion Therapeutics, Inc., where he spearheaded an initial public offering in 2014. Prior to joining Flexion, he served as Chief Financial Officer at Novavax, Inc. from 2009 to 2013. From 2008 to 2009, Fred Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. Prior to serving as Chief Executive Officer of Genelabs he was the Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Fred Driscoll served as Chief Executive Officer at OXiGENE, Inc., where he also served as Chairman of the Board and Audit Committee Chair. He was also a member of the Audit Committee for Cynapsus Therapeutics, Inc., which was sold to Sunovion Pharmaceuticals in 2016. Fred Driscoll earned a B.S. in accounting and finance from Bentley University. He is a member of the board of directors of Cellectar Biosciences, Inc., MEI Pharma, Inc. and NantKwest, Inc.
Follow Fred Driscoll:
About Flexion Therapeutics: Flexion Therapeutics is a biotechnology company that develops long-lasting intra-articular injection therapies to treat osteoarthritis.
Laurie Silver
Chief Financial Officer of BrainScope Company
Laurie Silver has over 20 years’ experience with a financial, accounting, strategic planning and operations background. Prior to BrainScope, she served as Director of Mergers and Acquisitions for the Services group at Symantec, where she led the integration of the Services organizations upon the $13 billion merger of Symantec and Veritas, which was the largest software company merger in history. Prior to Symantec, Ms. Silver was the Vice President of Finance and Administration of TrueCareers, a subsidiary of Sallie Mae; Manager of Financial Planning and Analysis across all business units of ABC/Disney; and a Senior Auditor at Ernst & Young LLP in New York. Ms. Silver graduated from the Stephen M. Ross School of Business at the University of Michigan and earned a CPA license from the State of New York. She has been with BrainScope since 2009.
Follow Laurie Silver:
About BrainScope Company: Brainscope is a medical neurotechnology company that improves brain health.
Nathan Weems
Chief Financial Officer of VitalConnect
Nathan has accrued over 13 years of operational excellence in management roles spanning finance, business development, and marketing, most recently serving as Sr. Director of Finance at Natera, a public Bay Area biotech company. Earlier experience includes tenure at a top Wall Street investment bank and Big-4 accounting firm. Nathan brings expertise in accounting, due diligence, market research, fund raising and investor relations. He holds a BA from the University of Southern California and an MBA from Wharton. When his HP 12C is not within reach, you can usually find Nathan on two wheels or two skis exploring the outdoors with his family.
Follow Nathan Weems:
About VitalConnect: VitalConnect is a wearable biosensor technology for wireless hospital and remote patient monitoring.
Frank Reynolds
Chairman of the Board, CEO, CFO, CSO & Co-Founder of PixarBio
Follow Frank Reynolds:
About PixarBio: PixarBio Corp is a specialty Biotechnology company focused on pre-clinical and commercial development of new products.
Mark A. Peters
Chief Financial Officer & Treasurer of Medrobotics
Mark Peters has over 25 years of finance leadership, operations management, business analytics and strategic planning experience in private and public companies, including successful IPO experience. Mr. Peters began his career with PricewaterhouseCoopers and IBM before focusing on high growth medtech companies. His medtech experience includes Chief Financial Officer and Vice President roles for Health Language, a private equity financed healthcare IT company acquired by Wolters Kluwer; IST, a venture funded spinal implant company acquired by Integra LifeSciences; Aura Medsystems, a venture funded tissue closure company founded on technology licensed from Harvard Medical School / Mass. General Hospital; and Seikagaku Corporation, a publicly traded biopharma manufacturer of endotoxin detection re-agents. Mr. Peters earned a BBA in Accounting from The University of Texas and an MBA in Finance from The University of Notre Dame, where he serves as a Director on the Mendoza College of Business Graduate Alumni Board. He previously served on the Board of Directors for MassMEDIC (Massachusetts Medical Device Industry Council) and is a licensed CPA.
Follow Mark A. Peters:
About Medrobotics: Medrobotics is a medical robotics company developing and commercializing the Flex Robotic System.
Melissa Epperly
Chief Financial Officer of Psioxus Therapeutics
Melissa Epperly is a senior finance executive with deep healthcare experience. Prior to joining PsiOxus, Melissa was CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology pharmaceutical company based in Princeton, NJ. At R-Pharm US she led corporate and business development, leading the integration of the asset purchase of Ixempra ® (a metastatic breast cancer treatment) from Bristol-Myers Squibb. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund, where she drove operational excellence in their portfolio companies to facilitate and enable exponential growth. Prior to that she was a Vice President at Goldman Sachs in equity research where she helped develop, build, and commercialize a novel, global equity research product for long-term investing, GS SUSTAIN, in the US and Europe. Before joining Goldman Sachs she was a management consultant with Bain & Company in New York and London, focused on international and US based pharmaceutical clients and private equity. She previously worked at Morgan Stanley in New York in healthcare investment banking and banking management, enabling pharmaceutical and biotech companies to accelerate growth through strategic MandA and capital raising. Melissa holds an MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.
Follow Melissa Epperly:
About Psioxus Therapeutics: Psioxus Therapeutics is a cancer gene therapy company delivers medicines of value to patients with cancer.
James M. O’Brien
Chief Financial Officer of Cognition Therapeutics
James M. O’Brien is the Chief Financial Officer at Cognition Therapeutics.
Follow James M. O’Brien:
About Cognition Therapeutics: Cognition Therapeutics develops new therapeutics to treat patients suffering from Alzheimer’s disease and other neurodegenerative disorders.
Tim Kelly
Chief Financial Officer of Praxis Precision Medicines
Tim Kelly is the Chief Financial Officer at Praxis Precision Medicines.
Follow Tim Kelly:
About Praxis Precision Medicines: Praxis Precision Medicines offers drug development services.
Hunter Smith
Chief Financial Officer of Rhythm Pharmaceuticals
Hunter Smith is the Chief Financial Officer at Rhythm Pharmaceuticals.
Follow Hunter Smith:
About Rhythm Pharmaceuticals: Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Jonathan Tu
CFO & Co-Founder of Fluxergy
Jonathan Tu is the Chief Financial Officer and Co-Founder at Fluxergy.
Follow Jonathan Tu:
About Fluxergy: Fluxergy is a biotechnology company that offers point-of-care testing, PCR, and medical diagnostics.
Vikram Jog
CFO of Fluidigm
Vikram Jog has served as our Chief Financial Officer since February 2008. From April 2005 to February 2008, Mr. Jog served as Chief Financial Officer for XDx, Inc., a molecular diagnostics company. From March 2003 to April 2005, Mr. Jog was a Vice President of Applera Corporation and Vice President of Finance for its related businesses, Celera Genomics and Celera Diagnostics. From April 2001 to March 2003, Mr. Jog was Vice President of Finance for Celera Diagnostics and Corporate Controller of Applera Corporation. Mr. Jog holds a Bachelor of Commerce degree from Delhi University and an M.B.A. from Temple University. Mr. Jog is a member of the American Institute of Certified Public Accountants.
Follow Vikram Jog:
About Fluidigm: Fluidigm is a biotech tools company that creates microfluidic-based chips and instrumentation for biological research.
Jeffrey Poulton
Chief Financial Officer of Shire
Jeffrey “Jeff” brings to the Board his financial, commercial and strategic acumen. Since joining Shire in 2003 he has held leadership positions in finance supporting the Neuroscience, Gastrointestinal and Rare Diseases business units as well as the positions of Interim Chief Financial Officer and Head of Investor Relations. In addition, Jeff oversaw the operations of the Rare Diseases business unit in North America, Latin America and Asia Pacific, as well as leading the integration of the legacy-Viropharma rare disease products into the Shire portfolio. Prior to joining Shire, Jeff spent time at Cinergy Corp. and PPG Industries in a variety of corporate finance and business development roles, in addition to serving as a commissioned officer in the U.S. Navy. He received a Bachelor of Arts in Economics from Duke University and a Master of Business Administration in Finance from the Kelly School of Business at Indiana University.
Follow Jeffrey Poulton:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
Kam Unninayar
CFO of Tetraphase Pharmaceuticals
Follow Kam Unninayar:
About Tetraphase Pharmaceuticals: Tetraphase Pharmaceuticals is a company leveraging a dynamic drug engine targeted at several significant disease categories.
Mario Wanderley
Chief Financial Officer of Entrinsic Bioscience
Mario Wanderley is Managing Partner at VGP – Venture Growth Partners.
Follow Mario Wanderley:
About CitizenGlobal, Entrinsic Bioscience, Venture Growth Partners: Entrinsic Bioscience leverages gold standard science and game-changing amino acid technology.
